AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Feb 19, 2021
31637_dirs_2021-02-18_5b0ab7ad-5a0e-41c7-8880-8c8d61500005.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-02-16
Reporting Person: Krognes Steve E. (CFO and Treasurer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-16 | Common Stock | S | 22684 | $64.271 | Disposed | 927316 | Indirect |
| 2021-02-16 | Common Stock | S | 10199 | $65.038 | Disposed | 917117 | Indirect |
| 2021-02-16 | Common Stock | S | 16616 | $66.201 | Disposed | 900501 | Indirect |
| 2021-02-16 | Common Stock | S | 501 | $66.803 | Disposed | 900000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 97587 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $63.63 to $64.625 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.63 to $65.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.64 to $66.60 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.66 to $67.075 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F7: Includes 80,358 restricted stock units.